Focused Alpha’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$222K Buy
1,556
+72
+5% +$10.9K 0.06% 241
2026
Q2
$233K Buy
+1,484
New +$222K 0.06% 247

Other funds holding NVS

Focused Alpha's NVS Position: Q3 2026 in Review

Focused Alpha increased its Novartis (NVS) stake by 4.9% in Q3 2026, buying an estimated $10.9K and bringing the position to 1,556 shares worth $222K. The position accounts for 0.06% of the portfolio, ranked #241.

Focused Alpha first reported a position in NVS in Q2 2026 and has held it in 2 quarters since. The position peaked at $233K in Q2 2026. 1,370 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Focused Alpha held 1,556 shares of Novartis worth $222K as of Q3 2026.
  • Focused Alpha bought 72 Novartis shares in Q3 2026, an estimated $10.9K.
  • Novartis made up 0.06% of Focused Alpha's portfolio in Q3 2026, its #241 holding.
  • Focused Alpha first reported a position in Novartis in Q2 2026 and has held it in 2 quarters since.
  • Focused Alpha's Novartis position peaked at $233K in Q2 2026.
  • 1,370 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Focused Alpha's 13F filing for Q3 2026, filed 20 Oct 2026.